08.03.2024 • NewsSandozOphthalmologyBiosimilars

Sandoz Acquires Ophthalmology Franchise from Coherus

In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.

The deal, which adds the biosimilar Cimerli (ranibizumab-eqrn) to Sandoz's portfolio, includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

Sandoz and Coherus entered into the transaction agreement in January 2024.

Keren Haruvi, president Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Cimerli, is an anti-VEGF therapy, is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss.

© Shutterstock
© Shutterstock

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis